# Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa

> **NCT02709876** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Stem Cells Arabia** · enrollment: 50 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT02709876
- **Lead sponsor:** Stem Cells Arabia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2020-09
- **Final completion:** 2021-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709876, "Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02709876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*